The Worldwide Sepsis Diagnostic Industry is Expected to Reach $1.2 Billion by 2030

2022-11-09

DUBLIN, Nov. 9, 2022 /PRNewswire/ -- The "Global Sepsis Diagnostic Market By Product, By Technology, By Method, By Usability, By Pathogen: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to

ResearchAndMarkets.com's offering.

The global sepsis diagnostic market valued at $569.49 million in 2020, and is estimated to reach $1207.58 million by 2030, growing at a CAGR of 7.8% from 2021 to 2030.

Sepsis is a life-threatening sickness that results from your body's immune system's response to an infection. Sepsis occurs when an existing infection causes the body's immune system to overreact. When an individual is sick, his/her immune system fights the infection by releasing proteins and other substances. When this response goes awry, it causes inflammation, which leads to sepsis. Bacterial infections are the most common cause of sepsis. Septic shock, a medical emergency, can result from severe sepsis. Septic shock is characterized by a fast drop in blood pressure, organ failure, and extensive tissue destruction. It can be lethal if left untreated.

The major factors that drive the growth of the global sepsis diagnostic market include increase in government funding for sepsis-related research activities and rise in prevalence of infectious diseases. In addition, increase in burden of sepsis and rise in global geriatric population propel the market growth. However, high cost of automated diagnostics devices is expected to impede the market growth.

Conversely, development of rapid diagnosis/point-of-care techniques for early sepsis diagnostics is anticipated to provide lucrative opportunities to market players during the forecast period.

The global sepsis diagnostic market is segmented into product type, technology, method, usability, pathogen, and region.

According to product type, the market is categorized into blood culture media, instruments, assay kits & reagents, and software. By technology, it is segregated into microbiology, molecular diagnostics, immunoassays, and flow cytometry. On the basis of method, the market is categorized into conventional diagnostics and automated diagnostics. By usability, the market is bifurcated into laboratory testing and point-of-care testing. Depending on pathogen, the market is segregated into bacterial sepsis, fungal sepsis, and other pathogen. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

The major companies profiled in the report include Abbott Laboratories, Inc., Becton, Dickinson and Company, Bruker Corporation, BioMerieux, Beckman Coulter, Inc., Danaher Corporation, Nanosphere, Inc., Hoffmann-LA Roche Ltd., T2 Biosystems Inc., Thermo Fisher Scientific Inc.

Key findings of the study

Depending on product, the blood culture media segment held the largest share in the global market in 2020.

On the basis of technique, the microbiology garnered the highest share in 2020, and is expected to remain dominant during the forecast period.

By method, the conventional diagnostic method segment dominated the market 2020, and is expected to continue this trend during the forecast period.

As per usability, the laboratory testing segment acquired the largest share in 2020, and is anticipated to lead in the coming years.

By pathogen, the bacterial sepsis segment held the largest market share in 2020, and is expected to remain dominant during the forecast period.

Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 8.9% during the forecast period.

Key Topics Covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter's five forces analysis

3.4. Top player positioning

3.5. Market dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT

4.1 Overview

4.1.1 Market size and forecast

4.2 Blood Culture Media

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Instruments

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Assay kits & Reagents

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Software

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

CHAPTER 5: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY

5.1 Overview

5.1.1 Market size and forecast

5.2 Microbiology

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Molecular Diagnostics

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Immunoassays

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

5.5 Flow Cytometry

5.5.1 Key market trends, growth factors and opportunities

5.5.2 Market size and forecast, by region

5.5.3 Market analysis by country

CHAPTER 6: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD

6.1 Overview

6.1.1 Market size and forecast

6.2 Conventional Diagnostics

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Automated Diagnostics

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

CHAPTER 7: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY

7.1 Overview

7.1.1 Market size and forecast

7.2 Laboratory Testing

7.2.1 Key market trends, growth factors and opportunities

7.2.2 Market size and forecast, by region

7.2.3 Market analysis by country

7.3 Point-of-care Testing

7.3.1 Key market trends, growth factors and opportunities

7.3.2 Market size and forecast, by region

7.3.3 Market analysis by country

CHAPTER 8: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN

8.1 Overview

8.1.1 Market size and forecast

8.2 Bacterial Sepsis

8.2.1 Key market trends, growth factors and opportunities

8.2.2 Market size and forecast, by region

8.2.3 Market analysis by country

8.3 Fungal Sepsis

8.3.1 Key market trends, growth factors and opportunities

8.3.2 Market size and forecast, by region

8.3.3 Market analysis by country

8.4 Others

8.4.1 Key market trends, growth factors and opportunities

8.4.2 Market size and forecast, by region

8.4.3 Market analysis by country

CHAPTER 9: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION

CHAPTER 10: COMPANY LANDSCAPE

10.1. Introduction

10.2. Top winning strategies

10.3. Product Mapping of Top 10 Player

10.4. Competitive Dashboard

10.5. Competitive Heatmap

10.6. Key developments

CHAPTER 11: COMPANY PROFILES

11.1

11.1.1 Company overview

11.1.2 Company snapshot

11.1.3 Operating business segments

11.1.4 Product portfolio

11.1.5 Business performance

11.1.6 Key strategic moves and developments

11.2 BioMerieux SA

11.2.1 Company overview

11.2.2 Company snapshot

11.2.3 Operating business segments

11.2.4 Product portfolio

11.2.5 Business performance

11.2.6 Key strategic moves and developments

11.3 Thermo Fisher Scientific Inc.

11.3.1 Company overview

11.3.2 Company snapshot

11.3.3 Operating business segments

11.3.4 Product portfolio

11.3.5 Business performance

11.3.6 Key strategic moves and developments

11.4 Abbott Laboratories, Inc.

11.4.1 Company overview

11.4.2 Company snapshot

11.4.3 Operating business segments

11.4.4 Product portfolio

11.4.5 Business performance

11.4.6 Key strategic moves and developments

11.5 Becton, Dickinson and Company

11.5.1 Company overview

11.5.2 Company snapshot

11.5.3 Operating business segments

11.5.4 Product portfolio

11.5.5 Business performance

11.5.6 Key strategic moves and developments

11.6 Bruker Corporation

11.6.1 Company overview

11.6.2 Company snapshot

11.6.3 Operating business segments

11.6.4 Product portfolio

11.6.5 Business performance

11.6.6 Key strategic moves and developments

11.7 Beckman Coulter, Inc.

11.7.1 Company overview

11.7.2 Company snapshot

11.7.3 Operating business segments

11.7.4 Product portfolio

11.7.5 Business performance

11.7.6 Key strategic moves and developments

11.8 T2 Biosystems, Inc

11.8.1 Company overview

11.8.2 Company snapshot

11.8.3 Operating business segments

11.8.4 Product portfolio

11.8.5 Business performance

11.8.6 Key strategic moves and developments

11.9 Nanosphere, Inc.

11.9.1 Company overview

11.9.2 Company snapshot

11.9.3 Operating business segments

11.9.4 Product portfolio

11.9.5 Business performance

11.9.6 Key strategic moves and developments

11.10 Hoffmann-LA Roche Ltd

11.10.1 Company overview

11.10.2 Company snapshot

11.10.3 Operating business segments

11.10.4 Product portfolio

11.10.5 Business performance

11.10.6 Key strategic moves and developments

11.11 Danaher Corporation

11.11.1 Company overview

11.11.2 Company snapshot

11.11.3 Operating business segments

11.11.4 Product portfolio

11.11.5 Business performance

11.11.6 Key strategic moves and developments

For more information about this report visit https://www.researchandmarkets.com/r/ntmi1m

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets